Overall, our in vivo model, through defining IS formation dynamics across anatomical sites in the system, could predict BiTE pharmacodynamics and changes in CD19 expression over time, and identify optimal dosing strategies based on baseline tumor characteristics. The gene discussed is CD19; the disease is neoplasm.